ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03038022
Recruitment Status : Completed
First Posted : January 31, 2017
Last Update Posted : January 25, 2018
Sponsor:
Information provided by (Responsible Party):
Madrigal Pharmaceuticals, Inc.

Brief Summary:
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with Heterozygous Familial Hypercholesterolemia (HeFH).

Condition or disease Intervention/treatment Phase
Heterozygous Familial Hypercholesterolemia Drug: MGL-3196 Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 116 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia
Actual Study Start Date : February 9, 2017
Actual Primary Completion Date : December 18, 2017
Actual Study Completion Date : January 15, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MGL-3196
Study Drug
Drug: MGL-3196
Oral

Placebo Comparator: Placebo
Matching Placebo
Drug: Placebo
Oral




Primary Outcome Measures :
  1. Mean percent change from baseline in low-density lipoprotein cholesterol (LDL-C) [ Time Frame: 12 Weeks ]

Secondary Outcome Measures :
  1. Safety and tolerability of MGL-3196 based on Adverse Events and Changes in Laboratory Values [ Time Frame: 12 Weeks ]
  2. Mean percent change from baseline on selected lipid parameters [ Time Frame: 12 Weeks ]
    Non-high-density lipoprotein cholesterol (non-HDL-C),Apolipoprotein B (ApoB), Total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) ratio, Triglycerides,Lipoprotein(a), Apolipoprotein A1 (ApoA1)/ApoB ratio, and Lipoprotein particle assessment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must be willing to participate in the study and provide written informed consent;
  • Male and female adults ≥18 years of age;
  • Female patients of child bearing potential with negative serum pregnancy (beta human chorionic gonadotropin) test who are not breastfeeding, do not plan to become pregnant during the study, and agree to use effective birth control (ie, condoms, diaphragm, non-hormonal intrauterine device [IUD], or sexual abstinence [only if this is in line with the patient's current lifestyle]) throughout the study and for at least 1 month after study completion; hormonal contraception (estrogens stable ≥3 months) and hormonal IUDs are permitted if used with a secondary birth control measure (eg, condoms); OR female patients of non-child bearing potential (ie, surgically [bilateral oophorectomy, hysterectomy, or tubal ligation] or naturally sterile [>12 consecutive months without menses]); male patients who have sexual intercourse with a female partner of child bearing potential from the first dose of study drug until 1 month after study completion must either be surgically sterile (confirmed by documented azoospermia >90 days after the procedure) OR agree to use a condom with spermicide. All male patients must agree not to donate sperm from the first dose of study drug until 1 month after study completion;
  • Must have a diagnosis of HeFH by genetic testing or by having met the diagnostic criteria for definite familial hypercholesterolemia outlined by the Simon Broome Register Group or WHO/Dutch Lipid Network (score >8);
  • Must have a fasting LDL-C ≥ 2.6 mmol/L (100 mg/dL); and
  • Must be on a stable or maximally tolerated dose (≥ 4 weeks prior to screening) of an approved statin (rosuvastatin ≤ 20 mg daily, atorvastatin ≤ 80 mg daily), with or without ezetimibe.

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • Low-density lipoprotein (LDL) or plasma apheresis within 2 months prior to randomization;
  • New York Heart Association class III or IV heart failure, or known left ventricular ejection fraction <30%;
  • Uncontrolled cardiac arrhythmia, including confirmed QT interval corrected using Fridericia's formula (QTcF) >450 msec for males and >470 msec for females at the screening electrocardiogram (ECG) assessment;
  • Myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass graft, or stroke within 3 months prior to randomization;
  • Type 1 diabetes, or newly diagnosed or uncontrolled type 2 diabetes (hemoglobin A1c [HbA1c] >8%);
  • History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to screening; Note: Significant alcohol consumption is defined as average of >20 g/day in female patients and >30 g/day in male patients;
  • Thyroid replacement therapy;
  • Evidence of chronic liver disease;
  • Hepatitis B, as defined by the presence of hepatitis B surface antigen;
  • Hepatitis C, as defined by the presence of hepatitis C virus (HCV) antibody (anti-HCV) and HCV ribonucleic acid (RNA). Patients with positive anti-HCV who test negative for HCV RNA at screening will be allowed to participate in the study;
  • Serum alanine aminotransferase (ALT) >1.5 × ULN (one repeat allowed);
  • Estimated glomerular filtration rate <60 mL/min;
  • Creatine kinase >3 × ULN (one repeat allowed);
  • History of biliary diversion;
  • Positive for human immunodeficiency virus infection;
  • History of malignant hypertension;
  • Systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening or randomization and confirmed at an unscheduled visit;
  • Triglycerides >5.7 mmol/L (500 mg/dL) at screening and confirmed by repeat assessment;
  • Active, serious medical disease with likely life expectancy <2 years;
  • Active substance abuse, including inhaled or injection drugs within the year prior to screening;
  • Participation in an investigational new drug trial within the 30 days prior to randomization; or
  • Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, or compromise the well-being of the patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03038022


Locations
Denmark
Madrigal Research Site
Aalborg, Denmark
Madrigal Research Site
Viborg, Denmark
Sponsors and Collaborators
Madrigal Pharmaceuticals, Inc.
Investigators
Study Director: Rebecca Taub, MD Madrigal Pharmaceuticals, Inc.

Responsible Party: Madrigal Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT03038022     History of Changes
Other Study ID Numbers: MGL-3196-06
First Posted: January 31, 2017    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Hypercholesterolemia
Hyperlipoproteinemia Type II
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias